初代細胞市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、來源、最終用戶、地區和競爭對手分類，2021-2031年

全球原細胞市場預計將從 2025 年的 21.3 億美元成長到 2031 年的 30.2 億美元，複合年成長率為 5.99%。

該市場由直接從活體組織中分離的細胞組成，這些細胞保留了供體的生理特性，是體外研究中永生化細胞株的更優替代方案。該領域的成長主要受慢性病日益增多以及生物製藥研究的擴展所驅動，後者需要精確的毒性和療效篩檢模型。根據美國製藥製造商協會 (PhRMA) 發布的《2024 年報告》，全球有超過 8000 種藥物處於臨床開發階段，如此龐大的研發管線直接推動了臨床前檢驗中對原代細胞的需求。

儘管市場成長環境良好，但組織來源的倫理和物流複雜性仍構成重大挑戰。取得高品質的人體組織需要嚴格遵守監管規定，且依賴有限的捐贈資源，這可能導致供應瓶頸，並限制特定細胞類型用於研究的取得。因此，取得必要的生物材料需要嚴格的採購流程，這構成了市場准入的一大障礙。

市場促進因素

全球癌症和慢性疾病發生率的不斷上升是推動市場發展的根本動力。研究人員被敦促優先使用初代細胞來模擬複雜的病理過程，因為與永生化細胞株相比，原代細胞具有更高的生理保真度。這些生物材料至關重要，尤其是在腫瘤學研究中，它們對於闡明腫瘤微環境和評估患者個體化的藥物反應至關重要。根據美國癌症協會發布的《2024年癌症事實與數據》，預計光在美國，當年就將新增2,001,140例癌症病例。日益加重的疾病負擔使得可預測的臨床前模型變得特別重要，並直接增加了對用於藥物發現和生物標記鑑定的健康組織和病變組織的需求。

同時，以細胞為基礎的研究經費顯著增加，從而加強了利用初代細胞進行高階篩檢所需的必要基礎設施。這筆資金流入使生技公司能夠擴大營運規模，並整合依賴這些供體來源細胞的複雜檢測平台。正如再生醫學聯盟在其2024年1月發布的「產業趨勢」簡報中所指出的，2023年全球再生醫學領域吸引了117億美元的投資。這一強勁的資金勢頭與高效的法規核准相輔相成。美國食品藥物管理局（FDA）在2023年核准了55種新療法，這是其歷史上單年核准數量第二高，進一步鞏固了對初代細胞的依賴，從而最大限度地減少後期臨床試驗的失敗率。

市場挑戰

全球初代細胞市場的擴張受到獲取人體組織相關的倫理和物流複雜性的顯著限制。獲得具有活性且高品質的細胞需要嚴格遵守法規結構和倫理知情同意程序，這導致採購時間延長。由於初代細胞必須直接從活體組織中分離，製造商嚴重依賴數量有限的合格供體，從而造成供應瓶頸，難以維持大規模生物製藥計劃所需的特定細胞類型的穩定庫存。

這些短缺直接影響研發活動的擴充性。當某些細胞類型無法取得時，毒性測試和藥物篩檢計畫就會延誤，這必然會增加製藥公司的營運成本。供體組織短缺仍然是影響材料供應的一個長期存在的問題。根據美國衛生資源和服務管理局 (HRSA) 的數據，到 2024 年，美國國家器官移植等待名單上的人數將超過 10.3 萬人，凸顯了器官和組織嚴重短缺的問題。人體組織供需之間的巨大差距極大地限制了可商業性生產的初代細胞數量。

市場趨勢

在監管壓力日益增加以及社會對符合倫理的研究模式的需求推動下，以人源取代動物實驗的方法正在從根本上重塑全球初代細胞市場。這項轉變優先考慮獲取人源初代細胞，以取代毒理學和安全性評估中的動物源性基材，旨在提高其與人類健康結果的生物學相關性。這種倫理調整的基礎是公民的實際參與，他們影響立法藍圖。根據善待動物組織（PETA）2025年4月發布的報告《歐盟分階段廢除動物實驗》，歐盟委員會制定分階段淘汰化學品安全評估中動物實驗的藍圖，正是對一項獲得超過120萬個檢驗簽名的歐洲公民舉措的直接回應。

同時，利用原代細胞建構的微生理系統正為供體特異性組織帶來極具價值的應用，其發展歷程也從簡單的2D培養演變為複雜的器官模擬環境。這些先進的平台（晶片器官）高度依賴高品質的原代細胞來複製生理功能，從而解決了傳統非臨床試驗中常見的轉化差距問題。隨著製藥開發商尋求降低高失敗率，這些系統的應用正在加速。根據《製藥外包》（Pharmaceutical Outsourcing）2025年3月刊報道，約92%至96%成功通過動物試驗的藥物最終在人體臨床試驗中失敗。這凸顯了市場對這些以人為中心的初代細胞模型的迫切需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球初代細胞市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 產品分解（造血系統、皮膚細胞、肝細胞、消化器官系統、肺、腎、心臟、肌肉骨骼系統）
  • 依來源（人源初代細胞、動物源初代細胞）
  • 依最終用戶（製藥公司、生技公司、CROS、學術機構）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美初代細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲初代細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區初代細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲初代細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲初代細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球初代細胞市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• AllCells
• ZenBio Inc.
• PromoCell
• Thermo Fisher Scientific Inc.
• Cell Biologics Inc.
• STEMCELL Technologies Inc.
• Merck KGaA
• American Type Culture Collection（ATCC）

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Primary Cells Market is projected to expand from USD 2.13 Billion in 2025 to USD 3.02 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 5.99%. This market consists of cells isolated directly from living tissue that retain the physiological traits of the donor, offering a superior alternative to immortalized cell lines for in vitro studies. The sector's growth is largely fueled by the rising prevalence of chronic diseases and the expanding biopharmaceutical research landscape, which requires accurate models for toxicity and efficacy screening. As reported by the Pharmaceutical Research and Manufacturers of America in 2024, there were over 8,000 medicines in clinical development globally, creating an extensive pipeline that directly amplifies the demand for primary cells during preclinical validation phases.

Despite these favorable growth conditions, the market faces significant hurdles related to the ethical and logistical complexities of tissue sourcing. Securing high-quality human tissue demands strict regulatory compliance and relies on a finite pool of donors, resulting in supply bottlenecks that can restrict the accessibility of specific cell types for research applications. Consequently, obtaining the necessary biological materials involves navigating stringent procurement processes, which acts as a substantial impediment to market accessibility.

Market Driver

The rising global incidence of cancer and chronic diseases serves as a fundamental catalyst for the market, prompting researchers to prioritize primary cells for modeling complex pathologies with higher physiological fidelity than immortalized lines. These biological materials are essential for oncology studies, particularly in deciphering tumor microenvironments and evaluating patient-specific drug responses. According to the American Cancer Society's 'Cancer Facts & Figures 2024', it was projected that 2,001,140 new cancer cases would be diagnosed in the United States alone during the year. This increasing disease burden necessitates predictive preclinical models, directly intensifying the demand for both healthy and diseased primary tissue for drug discovery and biomarker identification.

Concurrently, a significant increase in financial support for cell-based research is strengthening the infrastructure required for advanced screening utilizing primary cells. Capital inflows allow biotechnology entities to scale operations and integrate sophisticated assay platforms that depend on these donor-derived cells for validity. As noted by the Alliance for Regenerative Medicine in their January 2024 'State of the Industry' briefing, the regenerative medicine sector attracted $11.7 billion in global investment throughout 2023. This financial momentum is matched by high regulatory productivity; the U.S. Food and Drug Administration approved 55 novel therapeutics in 2023, the second-highest annual total in its history, further solidifying the reliance on primary cells to minimize late-stage clinical attrition.

Market Challenge

The expansion of the global primary cells market is significantly constrained by the ethical and logistical complexities associated with sourcing human tissue. Obtaining viable, high-quality cells requires strict adherence to regulatory frameworks and ethical consent procedures, which often prolongs procurement timelines. Because primary cells must be isolated directly from living tissue, manufacturers depend heavily on a limited pool of suitable donors, creating unavoidable supply bottlenecks that make it difficult to maintain consistent inventories of specific cell types required for large-scale biopharmaceutical projects.

These shortages directly impact the scalability of research and development operations. When specific cell types are unavailable, toxicity testing and drug screening timelines are delayed, inevitably increasing operational costs for pharmaceutical companies. The scarcity of donor tissue remains a persistent issue affecting material availability; according to the Health Resources and Services Administration, over 103,000 people were on the national transplant waiting list in the United States in 2024, highlighting the critical shortage of organs and tissues. This widespread gap between the demand for human tissue and available supply severely limits the volume of primary cells that can be commercially produced.

Market Trends

The shift toward human-derived alternatives to animal testing is fundamentally restructuring the global primary cells market, driven by intensifying regulatory pressure and public demand for ethically sourced research models. This transition prioritizes the acquisition of human primary cells to replace animal-derived substrates in toxicology and safety assessments, ensuring greater biological relevance for human health outcomes. The momentum for this ethical realignment is evidenced by substantial civic engagement influencing legislative roadmaps; according to PETA's April 2025 report on phasing out animal testing in the EU, the European Commission's development of a roadmap to phase out animal testing in chemical safety assessments was directly responsive to a European Citizens' Initiative that secured over 1.2 million verified signatures.

Simultaneously, the development of microphysiological systems using primary cells is creating a critical high-value application for donor-specific tissues, moving beyond simple 2D cultures to complex, organ-mimicking environments. These advanced platforms, or organ-on-chips, rely heavily on high-quality primary cells to replicate physiological functions, offering a solution to the translational gap often seen in traditional preclinical studies. The adoption of these systems is accelerating as pharmaceutical developers seek to mitigate high attrition rates; according to Pharmaceutical Outsourcing in March 2025, approximately 92% to 96% of drugs that successfully pass animal testing subsequently fail in human clinical trials, underscoring the urgent market necessity for these human-centric primary cell models.

Key Market Players

• AllCells
• ZenBio Inc.
• PromoCell
• Thermo Fisher Scientific Inc.
• Cell Biologics Inc.
• STEMCELL Technologies Inc.
• Merck KGaA
• American Type Culture Collection (ATCC)

Report Scope

In this report, the Global Primary Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Primary Cells Market, By Product

• Hematopoietic
• Dermatocytes
• Hepatocytes
• Gastrointestinal
• Lung
• Renal
• Heart
• Musculoskeletal

Primary Cells Market, By Origin

• Human Primary Cells
• Animal Primary Cells

Primary Cells Market, By End user

• Pharma Biotech
• CROS
• Academia

Primary Cells Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Primary Cells Market.

Available Customizations:

Global Primary Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Primary Cells Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal)
  • 5.2.2. By Origin (Human Primary Cells, Animal Primary Cells)
  • 5.2.3. By End user (Pharma Biotech, CROS, Academia)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Primary Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Origin
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Primary Cells Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Origin
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Primary Cells Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Origin
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Primary Cells Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Origin
      • 6.3.3.2.3. By End user

7. Europe Primary Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Origin
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Primary Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Origin
      • 7.3.1.2.3. By End user
  • 7.3.2. France Primary Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Origin
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Primary Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Origin
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Primary Cells Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Origin
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Primary Cells Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Origin
      • 7.3.5.2.3. By End user

8. Asia Pacific Primary Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Origin
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Primary Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Origin
      • 8.3.1.2.3. By End user
  • 8.3.2. India Primary Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Origin
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Primary Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Origin
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Primary Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Origin
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Primary Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Origin
      • 8.3.5.2.3. By End user

9. Middle East & Africa Primary Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Origin
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Primary Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Origin
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Primary Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Origin
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Primary Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Origin
      • 9.3.3.2.3. By End user

10. South America Primary Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Origin
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Primary Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Origin
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Primary Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Origin
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Primary Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Origin
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Primary Cells Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AllCells
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ZenBio Inc.
• 15.3. PromoCell
• 15.4. Thermo Fisher Scientific Inc.
• 15.5. Cell Biologics Inc.
• 15.6. STEMCELL Technologies Inc.
• 15.7. Merck KGaA
• 15.8. American Type Culture Collection (ATCC)

16. Strategic Recommendations

17. About Us & Disclaimer